Cargando…

Tocilizumab cost effective in reducing COVID-19-related deaths

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159658/ https://www.ncbi.nlm.nih.gov/pubmed/34075294 http://dx.doi.org/10.1007/s40274-021-7751-7

Ejemplares similares

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

Rapid COVID-19 movement restrictions reduce societal costs
Publicado: (2021)

Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
por: Witting, Celeste, et al.
Publicado: (2021)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

NSAID use does not increase risk of COVID-19-related death
Publicado: (2021)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

Testing and restrictions are cost-effective COVID-19 measures
Publicado: (2021)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

COVID-19 vaccination predicted to be cost effective in USA
Publicado: (2021)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Cost effective COVID-19 mitigation measures in US colleges
Publicado: (2021)

Productivity losses impact cost effectiveness of COVID-19 vaccine
Publicado: (2021)

Expanded testing for COVID-19 could be cost effective in USA
Publicado: (2020)

COVID-19 control strategies cost effective in South Africa
Publicado: (2020)

Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)

ICU bed reserve capacity for COVID-19 cost effective in Germany
Publicado: (2021)

Tocilizumab in the Management of COVID-19: A Preliminary Report
por: Li, Michael, et al.
Publicado: (2021)

Costs of active COVID-19 testing in Canada
Publicado: (2020)

Cost-benefit of COVID-19 lockdown in the UK
Publicado: (2020)

Chloroquine and hydroxychloroquine increase risk of death in COVID-19
Publicado: (2020)

Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
por: Zeng, Jia, et al.
Publicado: (2020)

Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA
Publicado: (2021)

Counting the cost of COVID-19 at the peak of the pandemic in Spain
Publicado: (2021)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

Estimated direct costs of COVID-19 pandemic high in Turkey, but true costs "undoubtedly higher"
Publicado: (2021)

COVID-19 INDUCED CARDIOMYOPATHY SUCCESSFULLY TREATED WITH TOCILIZUMAB
por: Fakhra, Sadaf, et al.
Publicado: (2022)

Telemedicine improves drug adherence and reduces OOP costs
Publicado: (2021)

Costs of ICU care during COVID-19 pandemic in USA
Publicado: (2021)

Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
por: Yanagida, Mitsuaki, et al.
Publicado: (2013)

Easing of COVID-19 social restrictions in England comes at a cost
Publicado: (2021)

COVID-19 pandemic associated with substantial costs in older Medicare beneficiaries
Publicado: (2021)

Expediting COVID-19 vaccination increases QALYs and saves costs in the USA
Publicado: (2021)

Substantial direct medical costs for symptomatic COVID-19 cases in the US
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Improvements in Intractable Lumbar and Lower-Extremity Symptoms after Systemic Administration of Tocilizumab, an Anti-interleukin-6 Receptor Antibody
por: Sainoh, Takeshi, et al.
Publicado: (2022)

Economic impact of avoidable cancer deaths due to COVID-19 pandemic 'substantial'
Publicado: (2021)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
Publicado: (2021)

National lockdown not cost effective in Israel during COVID-2 pandemic
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lblt2kqnijr0g45s8oocc6h3og